FT-018

**FT-018** is an investigational recombinant adeno-associated virus gene therapy being developed by Fronterra for **arrhythmogenic right ventricular cardiomyopathy**. It is listed in the company's cardiovascular pipeline as a **preclinical** program. The specific transgene, molecular target, and detailed mechanism of action have not been publicly disclosed, but the therapeutic concept is gene replacement or gene delivery using an rAAV vector for a genetic cardiomyopathy indication. Fronterra has also indicated preclinical research progress for FT-018 at the 2025 ASGCT Annual Meeting and uses a proprietary insect-cell-based rAAV manufacturing platform for its gene therapy programs.